Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 7/20 | 0.44 |
| ▸ | ITK | Q08881 | 7/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 7/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15345166 | 0.83 | MET (0.48) | METBTKITKPRMT5WDR77 | |
| SCHEMBL84584 | 0.77 | MET (0.42) | METBTKITKPRMT5WDR77 | |
| SCHEMBL20132695 | 0.75 | BRD4 (0.45) | BTKCDK9PIM1 | |
| SCHEMBL15341891 | 0.73 | PIM1 (0.40) | BTKCDK9PIM1 | |
| SCHEMBL19937778 | 0.72 | BTK (0.47) | METBTKITKPRMT5WDR77 | |
| SCHEMBL13466363 | 0.70 | MAPK8 (0.51) | PIM1 | |
| SCHEMBL13560244 | 0.70 | KIT (0.59) | BTKITKAXLNTRK1CCNT1 | |
| SCHEMBL15340892 | 0.69 | PIM1 (0.39) | PIM1 | |
| SCHEMBL11399098 | 0.69 | CCR1 (0.48) | BTKCDK9PIM1 | |
| SCHEMBL26528888 | 0.69 | PIM1 (0.33) | BTKCDK9PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MET 3530/4885BTK 1148/4885ITK 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.